Australia markets closed
  • ALL ORDS

    7,266.30
    +151.80 (+2.13%)
     
  • ASX 200

    6,988.10
    +149.80 (+2.19%)
     
  • AUD/USD

    0.6998
    -0.0035 (-0.50%)
     
  • OIL

    87.29
    +0.68 (+0.79%)
     
  • GOLD

    1,792.30
    -2.70 (-0.15%)
     
  • BTC-AUD

    54,003.34
    +403.51 (+0.75%)
     
  • CMC Crypto 200

    863.83
    +21.37 (+2.54%)
     
  • AUD/EUR

    0.6273
    -0.0035 (-0.56%)
     
  • AUD/NZD

    1.0675
    -0.0006 (-0.06%)
     
  • NZX 50

    11,852.15
    -198.17 (-1.64%)
     
  • NASDAQ

    14,454.61
    +451.50 (+3.22%)
     
  • FTSE

    7,466.07
    -88.24 (-1.17%)
     
  • Dow Jones

    34,725.47
    +564.69 (+1.65%)
     
  • DAX

    15,318.95
    -205.32 (-1.32%)
     
  • Hang Seng

    23,550.08
    -256.92 (-1.08%)
     
  • NIKKEI 225

    26,717.34
    +547.04 (+2.09%)
     

Afya Limited Announces Third-Quarter and Nine Months 2021 Financial Results

  • Oops!
    Something went wrong.
    Please try again later.
·32-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • AFYA

Strong growth
Record-High Cash Flow Generation
Expansion on Digital Services

NOVA LIMA, Brazil, November 22, 2021--(BUSINESS WIRE)--Afya Limited (NASDAQ: AFYA) ("Afya" or the "Company"), the leading medical education group and digital health service provider in Brazil, reported today financial and operating results for the three and nine-months period ended September 30, 2021 (third quarter 2021). Financial results are expressed in Brazilian Reais and are presented in accordance with International Financial Reporting Standards (IFRS).

Third Quarter 2021 Highlights

  • 3Q21 Adjusted Net Revenue increased 47.9% YoY to R$463.3 million.

  • 3Q21 Adjusted EBITDA increased 28.2% YoY reaching R$191.4 million, with an Adjusted EBITDA Margin of 41.3%.

Nine Months 2021 Highlights

  • 9M21 Adjusted Net Revenue increased 45.1% YoY to R$1,247.3 billion.

  • 9M21 Adjusted EBITDA increased 37.2% YoY reaching R$559.7 million, with an Adjusted EBITDA Margin of 44.9%.

  • Cash conversion of 113.5%, with a solid cash position of R$ 1,038.9 billion.

  • 247 thousand physicians and medical students in Afya’s ecosystem.

Table 1: Financial Highlights

For the three months period ended September 30,

For the nine months period ended September 30,

(in thousand of R$)

2021

2021 Ex
Acquisitions*

2020

% Chg

% Chg Ex
Acquisitions

2021

2021 Ex
Acquisitions*

2020

% Chg

% Chg Ex
Acquisitions

(a) Net Revenue

454,387

321,886

309,410

46.9%

4.0%

1,221,112

908,861

855,925

42.7%

6.2%

(b) Adjusted Net Revenue (1)

463,278

323,978

313,324

47.9%

3.4%

1,247,321

914,242

859,839

45.1%

6.3%

(c) Adjusted EBITDA (2)

191,400

127,268

149,269

28.2%

-14.7%

559,709

406,600

408,065

37.2%

-0.4%

(d) = (c)/(b) Adjusted EBITDA Margin

41.3%

39.3%

47.6%

-630 bps

-830 bps

44.9%

44.5%

47.5%

-260 bps

-300 bps

(e) Adjusted Net Income

116,875

63,752

115,503

1.2%

-44.8%

341,972

217,526

336,544

1.6%

-35.4%

* Ex Acquisitions: stands for the same companies that Afya consolidated in the same period of the previous year. For the three months period ended September 30, 2021, "2021 Ex Acquisitions" excludes: PEBMED (only July, 2021), FCMPB, MedPhone, FESAR, iClinic, Medicinae, Medical Harbour, Cliquefarma, Shosp, UNIFIPMoc, FIPGuanambi and UNIGRANRIO.

For the nine months period ended September 30, 2021 - "2021 Ex Acquisitions" excludes UniRedentor (only January, 2021; Closing of Uniredentor was in January 31,2020), UniSl (January to April, 2021; Closing of Unisl was in May,2020), PEBMED (only July, 2021; Closing of PEBMED was in July, 2020), FCMPB, Medphone, FESAR, iClinic, Medicinae, Medical Harbour, Cliquefarma, Shosp, UNIFIPMoc, FIPGuanambi and UNIGRANRIO.

1. Includes mandatory discounts in tuition fees granted by state decrees and individual/collective legal proceedings and public civil proceedings due to COVID 19 on site classes restriction and excludes recognized revenue that relates to discounts that were granted in 2H2020, but were invoiced in 1H21, based on the Supreme Court decision that was released in December 28, 2020.

2. See more information on "Non-GAAP Financial Measures" (Item 08).

1. Message from Management

Virgilio Gibbon, Afya’s CEO, stated:

The results of this quarter reinforce that our strategy has been successful, marked by the consistent growth of our operational and financial results, with significant increases in net revenue and EBITDA. We hope to see, in the near future, the pandemic losing its strength and opening wide paths for education to return to its practical mode, pushing our students, employees, and partners to continue extracting the best from our acquisitions and digital services.

As physicians handle a higher volume of work each year, we’re proud that our productivity tools are being able to help them throughout their medical journey. We have expanded our clinical decision software to 30 thousand additional physicians and medical students since the end of 2020, and we are now serving more than 30% of all Brazilian physicians and medical students with our offerings. We’ve reaffirmed our promises for the digital strategy shown on Afya’s Day, which is to ramp up our digital ecosystem with multiple offerings (B2C plus B2B) for the healthcare community, unlocking new interactions and revenue streams with pharma players, labs, pharmacy chains, hospitals, and HC operators through our platforms. The acquisitions we completed this quarter - RXPRO, for example -, reinforce our unique and complete offering for the medical career and pharma players

Along with that scenario, the expansion of our offering in the Undergrad business continues to grow strong, with the closing of the acquisition of UNIGRANRIO, in August 2021 and the start of operations of the Garanhuns’ medical school this month, in the State of Pernambuco, providing 428 new authorized undergraduate medical seats to Afya, reaching 2,731 seats so far. This represents almost 20 thousand students at maturity, with a CAGR of 10% from 2020 to 2026. Considering all acquisitions, we’ve added 1,279 seats since our IPO.

In this quarter, we also announced a relevant equity operation: after the successful completion of our first share repurchase program, a new share repurchase program was approved by our Board of Directors. We are confident in Afya, and under this new program, we may repurchase outstanding Class A common shares in the open market, beginning on October 2021.

As we’ve been presenting in each quarter, our ESG agenda is getting more and more robust, as we’ve embedded the theme in all we do and assume public positions that reveal our goals and push new ones. Reinforcing this agenda, along with the commitments we’ve already shown, in this quarter, we also announced that Sustainalytics, a leading ESG, and corporate governance research firm, has rated Afya as a "low risk" ESG Risk Rating company, placing it in the 10th percentile in the Sustainalytics database of over 13,500 organizations as of September 2021. We were considered as a Company at low risk of experiencing material financial impacts from ESG factors, due to our low exposure and good policies and applied practices.

As a reflection of our great results and actions that are being shown to the market, I’m also glad to announce that we’ve won two important awards this quarter. First, the Valor 1000 award, as "Best Company on the Education segment". And second, the "Época Negócios 360º" award, in two categories, as "Best Company in the Education segment" and "Sustainability in the Education segment". In the overall ranking of "Época Negócios 360º", Afya was rated as the 13th best company out of 428 companies participating.

This proves that our mission remains strong: to become the reference in medical and healthcare education and services, empowering students and physicians to transform their ambitions into rewarding lifelong experiences. This continues to guide our strategy and I am proud of what we have achieved so far, as well of what we are planning for the future.

2. Key Events in the Quarter:

  • Closing of UNIGRANRIO acquisition in August 2021 – a post-secondary education institution with government authorization to offer 308 undergraduate medical seats in the state of Rio de Janeiro. With this acquisition, Afya reaches 2,611 authorized medical seats. The aggregate purchase price (enterprise value) was R$700.0 million, including the assumption of estimated Net Debt of R$73.9 million. The equity value was paid 60% in cash on the transaction closing date and 40% will be paid in four equal annual installments, adjusted by the CDI rate. We expect an EV/EBITDA of 4.1x at maturity and post synergies.

  • Closing of Bertelsmann’s acquisition of Crescera’s stake in Afya in August 2021 - Crescera Educacional announced the sale of the entirety of its 23,074,134 Class B common shares of Afya to Bertelsmann. As a result of the closing of the transaction, Daniel Borghi and Laura Guaraná from Crescera ceased to be Afya board members. Mr. Borghi will continue to support Afya as a board observer for six months, starting on the transaction close date. Pursuant to Afya’s amended and restated articles of association, Shobhna Mohn and Kay Krafft were appointed by Bertelsmann as board members.

  • Afya assumed a voluntary commitment to have at least 50% of women in its management positions by 2030 in August 2021. In addition, Afya announced that it was certificated by Women on Board, an independent initiative whose purpose is to acknowledge, value and promote corporate environments in which women are part of the board of directors. The company voluntarily committed to continue having at least two women as board members.

  • Afya announces that Sustainalytics, a leading ESG and corporate governance research firm, has rated Afya as a "low risk" ESG Risk Rating company and placed it in the 10th percentile in the Sustainalytics database of over 13,500 organizations as of September 2021. Afya is at low risk of experiencing material financial impacts from ESG factors, due to its low exposure and good policies and applied practices.

3. Subsequent Events in the Quarter

  • Closing of RXPRO acquisition in October 2021 – a solution that connects physicians with the pharmaceutical industry, providing specialized and personalized marketing for those companies, in a more convenient way for physicians. RX PRO does this by delivering free samples to a community of pre-selected physicians and offering medical updates on pharmaceutical products and treatments in a fast and efficient way for doctors and, consequently, reducing pharma marketing and detailing costs.

  • Afya announced that, after the completion of its first share repurchase program on October 21, 2021, which resulted in the purchase of 1,015,844 Class A common shares, its Board of Directors has approved a new share repurchase program. Under this share repurchase program, Afya may repurchase up to 1,383,108 of its outstanding Class A common shares in the open market, based on prevailing market prices, or in privately negotiated transactions, beginning on October 28, 2021 until the earlier of completion of the repurchase or December 31, 2022, depending upon market conditions.

  • Afya announced that the Secretary of Regulation and Supervision of Higher Education of the Ministry of Education ("MEC") authorized the operation of the medical school in Garanhuns in the State of Pernambuco. On March 28, 2019, our shareholder Nicolau Carvalho Esteves entered into an agreement with Afya Brazil, in connection with the authorization of ITPAC Garanhuns Greenfield unit, in which Afya Brazil agreed to pay to Nicolau Carvalho Esteves the amount of R$900,000 multiplied by the number of medical school seats authorized by MEC. ITPAC Garanhuns authorization guaranteed 120 medical seats to Afya, totaling a purchase price of R$108 million, of which: 50% in cash on the transaction closing date and 50% in two equal annual installments, adjusted by the CDI rate. With this acquisition, Afya reaches 2,731 authorized medical seats.

  • On November 18, 2021 the Brazilian Federal Court of Justice (STF) decided, by majority of the votes, that any law suit with decisions to apply linear discounts in monthly tuition fees for private universities with respect to the COVID-19 pandemic are unconstitutional. Therefore, the Company shall not apply linear discounts in any active monthly tuition fees that are related to the effects to the Covid-19 pandemic.

4. Second Half 2021 Guidance Reiterated

The Company maintains the announced guidance for 2021, which takes into account the successfully concluded acceptances of new medical students for the second half of 2021 and the consolidation of the digital companies and medical schools acquisitions.

The guidance for 2021 added to our reported results for the 1H21 will total our full year 2021 as follows:

Guidance for 2021

Important considerations

2021 Adjusted Net Revenue is expected to be between R$1.720 million – R$1.760 million

2021 Adjusted EBITDA Margin is expected to be between 42.0%-44.0%

5. 9M21 Overview

Operational Review

Afya is the only company offering technological solutions to support physicians across every stage of the medical career, from undergraduate students in their medical school years through medical residency preparatory courses, medical specialization programs and continuing medical education. Afya is also positioned in digital health services, providing clinical decision apps and practice management tools as SAAS (Software as a Service).

The Company reports results for three distinct business units. The first, Undergrad – medical schools, other healthcare programs and ex-health degrees. Revenue is generated from the monthly tuition fees the Company charges students enrolled in the undergraduate programs. The second, Continuing Education – specialization programs and graduate courses. Revenue is also generated from the monthly tuition fees the Company charges students enrolled in the specialization and graduate courses. The third is Digital Services – digital services offered by the Company at every stage of the medical career. This business unit is divided into 6 pillars: Content & Technology for Medical Education, Clinical Decision Software, Practice Management Tools & Electronic Medical Records, Physician - Patient Relationship, Telemedicine, and Digital Prescription, and revenue is generated from printed books and e-books, which is recognized at the point in time when control is transferred to the customer and subscription fees (SaaS model).

Key Revenue Drivers – Undergraduate Courses

Table 2: Key Revenue Drivers

Nine months period ended September 30,

2021

2020

% Chg

Undergrad Programs

MEDICAL SCHOOL

Approved Seats (1)

2,611

1,866

39.9%

Operating Seats

2,361

1,516

55.7%

Total Students (end of period)

15,977

9,567

67.0%

Average Total Students

13,983

8,873

57.6%

Average Total Students (ex-Acquisitions)*

10,222

8,873

15.2%

Tuition Fees (Total - R$MM)

1,081,135

648,065

66.8%

Tuition Fees (ex- Acquisitions* - R$MM)

802,141

648,065

23.8%

Medical School Avg. Ticket (ex- Acquisitions* - R$/month)

8,719

8,115

7.4%

UNDERGRADUATE HEALTH SCIENCE

Total Students (end of period)

19,297

11,255

71.5%

Average Total Students

14,587

10,869

34.2%

Average Total Students (ex-Acquisitions)*

10,421

10,869

-4.1%

Tuition Fees (Total - R$MM)

157,342

110,447

42.5%

Tuition Fees (ex- Acquisitions* - R$MM)

103,654

110,447

-6.2%

OTHER UNDERGRADUATE

Total Students (end of period)

26,953

14,701

83.3%

Average Total Students

18,533

13,832

34.0%

Average Total Students (ex-Acquisitions)*

10,298

13,832

-25.5%

Tuition Fees (Total - R$MM)

161,063

124,919

28.9%

Tuition Fees (ex- Acquisitions* - R$MM)

107,533

124,919

-13.9%

TOTAL TUITION FEES

Tuition Fees (Total - R$MM)

1,399,540

883,431

58.4%

Tuition Fees (ex- Acquisitions* - R$MM)

1,013,328

883,431

14.7%

For the nine months period ended September 30, 2021 - "2021 Ex Acquisitions" excludes UniRedentor (only January, 2021; Closing of Uniredentor was in January 31,2020), UniSl (January to April, 2021; Closing of Unisl was in May,2020), FCMPB, FESAR, UNIFIPMoc, FIPGuanambi and UNIGRANRIO.

(1) This number does not include Garanhuns acquisition that contributed 120 seats.

Key Revenue Drivers – Continuing Education and Digital Services

Table 3: Key Revenue Drivers

Nine months period ended September 30,

2021

2020

% Chg

Continuing Education

Medical Specialization & Others

Total Students (end of period)

2,835

4,181

-32.2%

Average Total Students

3,273

4,294

-23.8%

Average Total Students (ex-Acquisitions)*

3,022

4,294

-29.6%

Net Revenue from courses (Total - R$MM)

51,481

81,739

-37.0%

Net Revenue from courses (ex- Acquisitions¹)

49,320

81,739

-39.7%

Digital Services

Content & Technology for Medical Education

Active Paying Students

Prep Courses & CME - B2C

16,878

11,684

44.5%

Prep Courses & CME - B2B

4,097

2,154

90.2%

Clinical Decision Software

Whitebook Active Payers

117,826

95,099

23.9%

Clinical Management Tools²

iClinic Active Payers

15,984

-

n.a

Digital Services Total Active Payers (end of period)

154,785

108,937

42.1%

Net Revenue from Services (Total - R$MM)

109,613

57,537

90.5%

Net Revenue From Services (ex-Acquisitions³)

64,713

57,537

12.5%

(1) For the nine months period ended September 30, 2021 - "2021 Ex Acquisitions" excludes UniRedentor (only January, 2021; Closing of Uniredentor was in January 31,2020)

(2) Clinical management tools includes Telemedicine and Digital Prescription features

(3) For the nine months period ended September 30, 2021 - "2021 Ex Acquisitions" excludes PEBMED (only July, 2021; Closing of PEBMED was in July, 2020), FCMPB, Medphone, FESAR, iClinic, Medicinae, Medical Harbour, Cliquefarma, Shosp.

Key Operational Drivers – Digital Services

Monthly Active Users (MaU) represents the number of unique individuals that consumed Digital Services content in the last 30 days of a specific period.

Total monthly active users reached 247 thousand, 34.7% higher than 2020.

Table 4: Key Operational Drivers for Digital Services - Monthly Active Users (MaU)

3Q21

2Q21

1Q21

3Q20

% Chg
3Q21/3Q20

Content & Technology for Medical Education

20,015

18,968

19,857

18,322

9.2%

Clinical Decision Software

194,082

181,138

173,959

165,035

17.6%

Clinical Management Tools¹

32,909

32,968

27,799

-

-

Total Monthly Active Users (MaU) - Digital Services

247,006

233,074

221,615

183,357

34.7%

1) Clinical management tools includes Telemedicine and Digital Prescription features

2) There may be an overlap of users among the pillars

Seasonality

Undergrad´s and Continuing Education tuition revenue are related to the admission process and monthly tuition fees charged to students over the period, therefore, the Company does not have significant fluctuations. On Digital Services, Medcel’s sales are concentrated in the first and last quarter of the year, as a result of enrollments of Medcel’s clients at the end and beginning of the year. The majority of Medcel’s revenue is derived from printed books and e-books, which is recognized at the point in time when control is transferred to the customer. All other Digital Services do not present any significant seasonality. Consequently, Digital Services generally has higher revenue and results from operations in the first and last quarter of the year compared to the second and third quarters of the year.

Revenue

Total Net Revenue for the third quarter of 2021 was R$ 454.4 million, an increase of 46.9% over the same period of the prior year, due to the maturation of medical seats, increase in the average ticket of Medical programs, expansion of Digital Services, and consolidation of acquisitions.

Adjusted Net Revenue in 3Q21 includes an impact of R$ 8.9 million due to the net temporary discounts in tuition fees granted by individual and collective legal proceedings and public civil proceedings related to COVID-19 totaling R$ 463.3 million, an increase of 47.9% over the same period of the prior year. Excluding acquisitions, Adjusted Net Revenue in the third quarter increased 3.4% YoY to R$ 324.0 million, mainly impacted by Continuing Education revenue that decreased in R$13.2 million and the positive impact of deferred revenue in R$12.7 million in the 3Q20.

The Continuing Education business reported a decrease in Net Revenue in the three-months and the nine-months period ended September 30, 2021 due to a reduction in active paying students because of: (a) practical programs that are not being offered since 1H20 and, (b) physicians’ decision to postpone admission to specialization courses due to the COVID-19 pandemic. Nevertheless, with the combination of the opening of 6 new campuses in 2021 and expansion of the specialization’s portfolio, IPEMED’s intake process finished with an increase in top line on October 2021 yoy, after three quarters of decrease in Net Revenue.

For the nine-months period ended September 30, 2021, Total Net Revenue was R$ 1,221.1 billion, an increase of 42.7% over the same period of last year. Adjusted Net Revenue presented an increase of 45.1% over the same period of last year, totaling R$ 1,247.3 billion. Excluding acquisitions, Adjusted Net Revenue in the nine-months period increased 6.3% YoY to R$ 914.2 million, mainly due to the same reasons explained above.

Table 5: Revenue & Revenue Mix

(in thousands of R$)

For the three months period ended September 30,

For the nine months period ended September 30,

2021

2021 Ex
Acquisitions*

2020

% Chg

% Chg Ex
Acquisitions

2021

2021 Ex
Acquisitions*

2020

% Chg

% Chg Ex
Acquisitions

Net Revenue Mix

Undergrad

410,059

289,537

266,382

53.9%

8.7%

1,060,345

795,155

718,268

47.6%

10.7%

Adjusted Undergrad¹

418,950

291,629

270,296

55.0%

7.9%

1,086,554

800,536

722,182

50.5%

10.8%

Continuing Education

16,209

16,209

29,414

-44.9%

-44.9%

51,481

49,320

81,739

-37.0%

-39.7%

Digital Services

27,948

15,968

14,256

96.0%

12.0%

109,613

64,713

57,537

90.5%

12.5%

Inter-segment transactions

171

171

- 642

n.a

n.a

- 327

- 327

- 1,619

-79.8%

-79.8%

Total Reported Net Revenue

454,387

321,886

309,410

46.9%

4.0%

1,221,112

908,861

855,925

42.7%

6.2%

Total Adjusted Net Revenue ¹

463,278

323,978

313,324

47.9%

3.4%

1,247,321

914,242

859,839

45.1%

6.3%

* Ex Acquisitions: stands for the same companies that Afya consolidated in the same period of the previous year. For the three months period ended September 30, 2021, "2021 Ex Acquisitions" excludes: PEBMED (only July, 2021), FCMPB, MedPhone, FESAR, iClinic, Medicinae, Medical Harbour, Cliquefarma, Shosp, UNIFIPMoc, FIPGuanambi and UNIGRANRIO.

For the nine months period ended September 30, 2021 - "2021 Ex Acquisitions" excludes UniRedentor (only January, 2021; Closing of Uniredentor was in January 31,2020), UniSl (January to April, 2021; Closing of Unisl was in May,2020), PEBMED (only July, 2021; Closing of PEBMED was in July, 2020), FCMPB, Medphone, FESAR, iClinic, Medicinae, Medical Harbour, Cliquefarma, Shosp, UNIFIPMoc, FIPGuanambi and UNIGRANRIO.

1. Includes mandatory discounts in tuition fees granted by state decrees and individual/collective legal proceedings and public civil proceedings due to COVID 19 on site classes restriction and excludes recognized revenue that relates to discounts that were granted in 2H2020, but were invoiced in 1H21, based on the Supreme Court decision that was released in December 28, 2020.

2. See more information on "Non-GAAP Financial Measures" (Item 08).

Adjusted EBITDA

Adjusted EBITDA for the three-months period ended September 30, 2021 increased 28.2% to R$ 191.4 million, up from R$ 149.3 million in the same period of the prior year. For the nine-months period ended September 30, 2021, Adjusted EBITDA was R$ 559.7 million, an increase of 37.2% from the same period last year. The adjusted EBITDA Margins of both periods were below the reported margins of last year, mainly due to: 1) the consolidation of PEBMED, iClinic, MedPhone, Medicinae, Medical Harbour, Cliquefarma, Shosp, that reduced the digital operational margin; 2) the consolidation of UNIFIPMoc and UNIGRANRIO that are performing better than expected but still presenting lower margins when compared to the integrated companies; 3) lower performance from Continuing Education, as explained on the topic "Revenue"; 4) R$ 12.7 million of deferred revenue that positively impacted 3Q20 results.

Excluding the consolidation of acquisitions, Adjusted EBITDA for the three-months period ended September 30, 2021 decreased 14.7% to R$ 127.3 million, down from R$ 149.3 million in the same period of the prior year. For the nine-months period ended September 30, 2021, Adjusted EBITDA decreased 0.4% YoY to R$ 406.6 million from R$ 408.1 million, while the Adjusted EBITDA Margin decreased 300 basis points to 44.5%. The adjusted EBITDA Margins of both periods were below the reported margins of last year, mainly due to lower performance from Continuing Education and R$ 12.7 million of deferred revenue that positively impacted 3Q20 results, as explained on the topic "Revenue".

Table 6: Adjusted EBITDA

(in thousands of R$)

For the three months period ended September 30,

For the nine months period ended September 30,

2021

2021 Ex
Acquisitions*

2020

% Chg

% Chg Ex
Acquisitions

2021

2021 Ex
Acquisitions*

2020

% Chg

% Chg Ex
Acquisitions

Adjusted EBITDA

191,400

127,268

149,269

28.2%

-14.7%

559,709

406,600

408,065

37.2%

-0.4%

% Margin

41.3%

39.3%

47.6%

-630 bps

-830 bps

44.9%

44.5%

47.5%

-260 bps

-300 bps

* Ex Acquisitions: stands for the same companies that Afya consolidated in the same period of the previous year. For the three months period ended September 30, 2021, "2021 Ex Acquisitions" excludes: PEBMED (only July, 2021), FCMPB, MedPhone, FESAR, iClinic, Medicinae, Medical Harbour, Cliquefarma, Shosp, UNIFIPMoc, FIPGuanambi and UNIGRANRIO.

For the nine months period ended September 30, 2021 - "2021 Ex Acquisitions" excludes UniRedentor (only January, 2021; Closing of Uniredentor was in January 31,2020), UniSl (January to April, 2021; Closing of Unisl was in May,2020), PEBMED (only July, 2021; Closing of PEBMED was in July, 2020), FCMPB, Medphone, FESAR, iClinic, Medicinae, Medical Harbour, Cliquefarma, Shosp, UNIFIPMoc, FIPGuanambi and UNIGRANRIO.

Adjusted Net Income

Adjusted Net Income for the third quarter of 2021 was R$ 116.9 million, an increase of 1.2% over the same period of the prior year, mainly due to a decrease in net financial result that was affected by higher debt position and the increase in the average CDI, partially offset by higher income from financial investments.

For the nine-months period ended September 30, 2021, Adjusted Net Income totaled R$ 342.0 million, an increase of 1.6% over the same period from the prior year, mainly affected by the quarter’s net financial result, as explained above.

(in thousands of R$)

For the three months period ended
September 30,

For the nine months period ended
September 30,

2021

2020

% Chg

2021

2020

% Chg

Net income

57,989

79,575

-27.1%

193,282

247,131

-21.8%

Amortization of customer relationships and trademark (1)

18,031

11,597

55.5%

46,015

36,013

27.8%

Share-based compensation

8,847

10,052

-12.0%

33,949

24,649

37.7%

Non-recurring expenses:

32,008

14,279

124.2%

68,726

28,751

139.0%

- Integration of new companies (2)

5,192

2,761

88.0%

12,728

7,743

64.4%

- M&A advisory and due diligence (3)

8,442

3,709

127.6%

11,998

9,345

28.4%

- Expansion projects (4)

3,069

795

286.0%

6,459

2,886

123.8%

- Restructuring expenses (5)

6,414

3,101

106.8%

11,332

4,863

133.0%

- Mandatory Discounts in Tuition Fees (6)

8,891

3,914

127.2%

26,209

3,914

569.6%

Adjusted Net Income

116,875

115,503

1.2%

341,972

336,544

1.6%

Basic earnings per share - R$ (7)

0.57

0.80

-28.8%

1.91

2.54

-24.8%

(1) Consists of amortization of customer relationships and trademark recorded under business combinations.

(2) Consists of expenses related to the integration of newly acquired companies.

(3) Consists of expenses related to professional and consultant fees in connection with due diligence services for our M&A transactions.

(4) Consists of expenses related to professional and consultant fees in connection with the opening of new campuses.

(5) Consists of expenses related to the employee redundancies in connection with the organizational restructuring of our acquired companies.

(6) Consists of mandatory discounts in tuition fees granted by state decrees, individual/collective legal proceedings and public civil proceedings due to COVID 19 on site classes restriction and excludes recognized revenue that relates to discounts that were granted in 2H2020, but were invoiced in 1H21, based on the Supreme Court decision that was released in December 28, 2020.

(7) Basic earnings per share: Net Income/Total number of shares.

Cash and Debt Position

For the nine-months period ended September 30, 2021, Afya reported Cash Flow from Operations of R$ 528.7 million, up from R$ 308.9 million in same period of the previous year, an increase of 71.1% YoY.

Operating Cash Conversion Ratio for the nine-months period ended September 30, 2021 was 113.5%, compared with 85.6% in same period of the previous year. This increase was mainly due to a growth a reduction in trade receivables which was affected by the end of grace period of tuition renegotiation that occurred in 2020. This increase was mainly due to a reduction in trade receivables position that was affected by the end of grace period of tuition renegotiation that occurred in 2020.

Cash and cash equivalents in September 30, 2021 were R$ 1,038.9 billion, stable when compared to December 2020.

On September 30, 2021, net debt, excluding the effect of IFRS 16, totaled R$ 1,108.6 billion, compared with a net debt of R$ 166.9 million on December 31, 2020, mainly due to the closing of UNIFIPMoc, FipGuanambi and Unigranrio acquisitions, which were paid in cash the amount of R$ 704.6 million.

Table 8: Operating Cash Conversion Ratio Reconciliation

For the nine months period ended September 30,

(in thousands of R$)

Considering the adoption of IFRS 16

2021

2020

% Chg

(a) Cash flow from operations

528,698

308,916

71.1%

(b) Income taxes paid

28,495

15,830

80.0%

(c) = (a) + (b) Adjusted cash flow from operations

557,193

324,746

71.6%

(d) Adjusted EBITDA

559,709

408,065

37.2%

(e) Non-recurring expenses:

68,726

28,751

139.0%

- Integration of new companies (1)

12,728

7,743

64.4%

- M&A advisory and due diligence (2)

11,998

9,345

28.4%

- Expansion projects (3)

6,459

2,886

123.8%

- Restructuring Expenses (4)

11,332

4,863

133.0%

- Mandatory Discounts in Tuition Fees (5)

26,209

3,914

569.6%

(f) = (d) - (e) Adjusted EBITDA ex- non-recurring expenses

490,983

379,314

29.4%

(g) = (a) / (f) Operating cash conversion ratio

113.5%

85.6%

2790 bps

(1) Consists of expenses related to the integration of newly acquired companies.

(2) Consists of expenses related to professional and consultant fees in connection with due diligence services for M&A transactions.

(3) Consists of expenses related to professional and consultant fees in connection with the opening of new campuses.

(4) Consists of expenses related to the employee redundancies in connection with the organizational restructuring of acquired companies.

(5) Consists of mandatory discounts in tuition fees granted by state decrees and individual/collective legal proceedings and public civil proceedings due to COVID 19 on site classes restriction and excludes recognized revenue that relates to discounts that were granted in 2H2020, but were invoiced in 1H21, based on the Supreme Court decision that was released in December 28, 2020.

Table 9: Cash and Debt Position

(in thousands of R$)

3Q21

FY2020

% Chg

3Q20

% Chg

(+) Cash and Cash Equivalents

1,038,934

1,045,042

-0.6%

1,065,232

-2.5%

Cash and Bank Deposits

75,635

57,729

31.0%

32,331

133.9%

Cash Equivalents

963,299

987,313

-2.4%

1,032,901

-6.7%

(-) Loans and Financing

1,377,810

617,485

123.1%

160,256

759.8%

Current

14,780

107,162

-86.2%

143,081

-89.7%

Non-Current

1,363,030

510,323

167.1%

17,175

7836.1%

(-) Accounts Payable to Selling Shareholders

696,521

518,240

34.4%

362,261

92.3%

Current

247,819

188,420

31.5%

138,627

78.8%

Non-Current

448,702

329,820

36.0%

223,634

100.6%

(-) Other Short and Long Term Obligations

73,212

76,181

-3.9%

76,627

-4.5%

(=) Net Debt (Cash) excluding IFRS 16

1,108,609

166,864

564.4%

-466,088

-135.8%

(-) Lease Liabilities

675,895

447,703

51.0%

412,685

8.5%

Current

24,169

61,976

-61.0%

56,628

9.4%

Non-Current

651,726

385,727

69.0%

356,057

8.3%

Net Debt (Cash) with IFRS 16

1,784,504

614,567

190.4%

-53,403

n/a

ESG Metrics

ESG commitment is an important part of Afya’s strategy and permeates the Company’s core values. Afya has been advancing year after year on its core pillars and, going forward, ESG metrics will be disclosed in the Company’s quarterly financial results.

In August 2021, Afya assumed a voluntary commitment to have at least 50% of women in its management positions by 2030. In addition, Afya announced that it was certificated by Women on Board, an independent initiative whose purpose is to acknowledge, value and promote corporate environments in which women are part of the board of directors. The company voluntarily committed to continue having at least two women as board members.

In September 2021, Afya announced that Sustainalytics, a leading ESG and corporate governance research firm, has rated Afya as a "low risk" ESG Risk Rating company and placed it in the 10th percentile in the Sustainalytics database of over 13,500 organizations as of September, 2021. Afya is at low risk of experiencing material financial impacts from ESG factors, due to its low exposure, good policies and applied practices.

Table 10: ESG Metrics

3Q21

2Q21

1Q21

2020

2019

#

Governance and Employee Management

1

Number of employees

8,177

6,806

6,012

6,100

3,369

2

Percentage of female employees

55%

55%

55%

55%

57%

3

Percentage of female employees in the board of directors

18%

18%

18%

18%

22%

4

Percentage of independent member in the board of directors

36%

36%

36%

36%

22%

Environmental

4

Total energy consumption (kWh)

2,143,023

1,493,572

1,877,353

6,428,382

5,928,450

4.1

Consumption per campus

79,371

57,445

69,532

257,135

395,230

5

% supplied by distribution companies

83.54%

85.19%

90.0%

87.4%

96.2%

6

% supplied by other sources

16.46%

14.81%

10.0%

12.6%

3.8%

7

Greenhouse gas emissions (tons)

81.6

82.6

99

397

445

Social

8

Number of free clinical consultations offered by Afya

144,832

93,802

62,096

427,184

270,000

9

Number of physicians graduated in Afya's campuses

17,083

13,002

n.a

12,691

8,306

10

Number of students with financing and scholarship programs (FIES and PROUNI)

7,940

5,995

5,789

4,999

2,808

11

% of the undergraduate students

13.0%

13.7%

15.9%

13.7%

11.7%

12

Hospital and clinics partnership

725

443

432

432

60

6. Conference Call and Webcast Information

When:

November 22, 2021 at 05:00 p.m. ET.

Who:

Mr. Virgilio Gibbon, Chief Executive Officer

Mr. Luis André Blanco, Chief Financial Officer

Ms. Renata Costa Couto, Director of Investor Relations

Dial-in:

Brazil: +55 11 4680 6788 or +55 11 4700 9668 or +55 21 3958 7888 or +55 11 4632 2236 or +55 11 4632 2237

United States: +1 301 715 8592 or +1 312 626 6799 or +1 929 205 6099 or +1 253 215 8782 or +1 346 248 7799 or +1 669 900 6833

Webinar ID: 922 9097 2398

Other Numbers: https://afya.zoom.us/u/afDRvHHeL

OR

Webcast: https://afya.zoom.us/j/92290972398

Webinar ID: 922 9097 2398

About Afya Limited (NASDAQ: AFYA)

Afya is the leading medical education group in Brazil based on number of medical school seats. It delivers an end-to-end physician-centric ecosystem that serves and empowers students to be lifelong medical learners, from the moment they enroll as medical students, through their medical residency preparation, graduate program, and continuing medical education activities. Afya also offers content and clinical decision applications for healthcare professionals through its products WhiteBook, Nursebook, Medphone, MEDCEL, Medical Harbour and Portal PEBMED. For more information, please visit www.afya.com.br.

7. Forward – Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which statements involve substantial risks and uncertainties. All statements other than statements of historical fact could be deemed forward looking, and include risks and uncertainties related to statements about our competition; our ability to attract, upsell and retain students; our ability to increase tuition prices and prep course fees; our ability to anticipate and meet the evolving needs of students and professors; our ability to source and successfully integrate acquisitions; general market, political, economic, and business conditions; and our financial targets such as revenue, share count and IFRS and non-IFRS financial measures including gross margin, operating margin, net income (loss) per diluted share, and free cash flow. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the potential impacts of the COVID-19 pandemic on our business operations, financial results and financial position and the Brazilian economy.

The Company undertakes no obligation to update any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law. The achievement or success of the matters covered by such forward-looking statements involves known and unknown risks, uncertainties and assumptions. If any such risks or uncertainties materialize or if any of the assumptions prove incorrect, our results could differ materially from the results expressed or implied by the forward-looking statements we make. Readers should not rely upon forward-looking statements as predictions of future events. Forward-looking statements represent management’s beliefs and assumptions only as of the date such statements are made. Further information on these and other factors that could affect the Company’s financial results are included in the filings made with the United States Securities and Exchange Commission (SEC) from time to time, including the section titled "Risk Factors" in the most recent Rule 434(b) prospectus. These documents are available on the SEC Filings section of the investor relations section of our website at: https://ir.afya.com.br/.

8. Non-GAAP Financial Measures

To supplement the Company's consolidated financial statements, which are prepared and presented in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board—IASB, Afya uses Adjusted EBITDA and Operating Cash Conversion Ratio information, which are non-GAAP financial measures, for the convenience of investors. A non-GAAP financial measure is generally defined as one that intends to measure financial performance but excludes or includes amounts that would not be equally adjusted in the most comparable GAAP measure.

Afya calculates Adjusted EBITDA as net income plus/minus net financial result plus income taxes expense plus depreciation and amortization plus interest received on late payments of monthly tuition fees, plus share-based compensation plus/minus share of income of associate plus/minus non-recurring expenses. The calculation of Adjusted Net Income is net income plus amortization of customer relationships and trademark, plus share-based compensation. We calculate Operating Cash Conversion Ratio as the cash flow from operations, adjusted with income taxes paid divided by Adjusted EBITDA plus/minus non-recurring expenses.

Management presents Adjusted EBITDA, because it believes these measures provide investors with a supplemental measure of financial performance of the core operations that facilitates period-to-period comparisons on a consistent basis. Afya also presents Operating Cash Conversion Ratio because it believes this measure provides investors with a measure of how efficiently the Company converts EBITDA into cash. The non-GAAP financial measures described in this prospectus are not a substitute for the IFRS measures of earnings. Additionally, calculations of Adjusted EBITDA and Operating Cash Conversion Ratio may be different from the calculations used by other companies, including competitors in the education services industry, and therefore, Afya’s measures may not be comparable to those of other companies.

9. Investor Relations Contact

Renata Couto, Director of Investor Relations
Phone: +55 31 3515.7564 | +55 31 98463.3341
E-mail: renata.couto@afya.com.br

10. Financial Tables

Consolidated statements of income

For the three and nine months period ended September 30, 2021 and 2020

(In thousands of Brazilian Reais, except earnings per share)

Three-month period ended

Nine-month period ended

September 30,
2021

September 30,
2020

September 30,
2021

September 30,
2020

(unaudited)

(unaudited)

(unaudited)

(unaudited)

Net revenue

454,387

309,410

1,221,112

855,925

Cost of services

(180,042)

(112,292)

(450,993)

(308,226)

Gross profit

274,345

197,118

770,119

547,699

General and administrative expenses

(178,811)

(104,718)

(444,399)

(281,480)

Other (expenses) income, net

(135)

1,997

1,163

1,249

Operating income

95,399

94,397

326,883

267,468

Finance income

29,161

12,081

45,144

55,801

Finance expenses

(64,558)

(23,701)

(168,825)

(65,443)

Finance result

(35,397)

(11,620)

(123,681)

(9,642)

Share of income of associate

3,004

1,488

8,626

6,393

Income before income taxes

63,006

84,265

211,828

264,219

Income taxes expenses

(5,017)

(4,690)

(18,546)

(17,088)

Net income

57,989

79,575

193,282

247,131

Other comprehensive income

-

-

-

-

Total comprehensive income

57,989

79,575

193,282

247,131

Net income attributable to

Equity holders of the parent

53,030

74,832

178,357

235,327

Non-controlling interests

4,959

4,743

14,925

11,804

57,989

79,575

193,282

247,131

Basic earnings per share

Per common share

0.57

0.80

1.91

2.54

Diluted earnings per share

Per common share

0.56

0.79

1.89

2.52

Consolidated balance sheets - For the nine months period ended September 30, 2021 and for the twelve months period ended December, 31 2020

(In thousands of Brazilian Reais)

September 30, 2021

December 31, 2020

Assets

(unaudited)

Current assets

Cash and cash equivalents

1,038,934

1,045,042

Trade receivables

329,329

302,317

Inventories

9,093

7,509

Recoverable taxes

31,368

21,019

Other assets

24,885

29,614

Total current assets

1,433,609

1,405,501

Non-current assets

Restricted cash

-

2,053

Trade receivables

26,176

7,627

Other assets

186,563

74,037

Investment in associate

54,266

51,410

Property and equipment

399,458

260,381

Right-of-use assets

631,737

419,074

Intangible assets

3,755,011

2,573,010

Total non-current assets

5,053,211

3,387,592

Total assets

6,486,820

4,793,093

Liabilities

Current liabilities

Trade payables

47,020

35,743

Loans and financing

14,780

107,162

Lease liabilities

24,169

61,976

Accounts payable to selling shareholders

247,819

188,420

Notes payable

13,294

10,503

Advances from customers

87,995

63,839

Labor and social obligations

161,788

77,855

Taxes payable

31,704

32,976

Income taxes payable

11,581

4,574

Other liabilities

19,337

6,331

Total current liabilities

659,487

589,379

Non-current liabilities

Loans and financing

1,363,030

510,323

Lease liabilities

651,726

385,727

Accounts payable to selling shareholders

448,702

329,820

Notes payable

59,918

65,678

Taxes payable

99,789

21,425

Provision for legal proceedings

146,909

53,139

Other liabilities

3,231

3,822

Total non-current liabilities

2,773,305

1,369,934

Total liabilities

3,432,792

1,959,313

Equity

Share capital

17

17

Additional paid-in capital

2,376,699

2,323,488

Share-based compensation reserve

84,673

50,724

Treasury shares

(44,531)

-

Retained earnings

586,348

407,991

Equity attributable to equity holders of the parent

3,003,206

2,782,220

Non-controlling interests

50,822

51,560

Total equity

3,054,028

2,833,780

Total liabilities and equity

6,486,820

4,793,093

Consolidated statements of cash flow - For nine month period ended September 30, 2021 and 2020

(In thousands of Brazilian Reais)

September 30, 2021

September 30, 2020

(unaudited)

(unaudited)

Operating activities

Income before income taxes

211,828

264,219

Adjustments to reconcile income before income taxes

Depreciation and amortization

112,204

77,729

Disposals of property, equipment and intangible assets

2,985

-

Allowance for doubtful accounts

34,005

22,899

Share-based compensation expense

33,949

24,649

Net foreign exchange differences

18,376

1,613

Net (gain) loss on derivatives

-

(22,199)

Accrued interest

66,851

16,161

Accrued lease interest

47,738

32,123

Share of income of associate

(8,626)

(6,393)

Provision for legal proceedings

9,286

(93)

Changes in assets and liabilities

Trade receivables

(18,593)

(95,563)

Inventories

(1,232)

(1,436)

Recoverable taxes

(8,228)

(1,437)

Other assets

(11,264)

(6,820)

Trade payables

3,461

1,759

Taxes payables

(1,247)

(5,612)

Advances from customers

9,419

(18,882)

Labor and social obligations

54,005

42,033

Other liabilities

2,276

(4)

557,193

324,746

Income taxes paid

(28,495)

(15,830)

Net cash flows from operating activities

528,698

308,916

Investing activities

Acquisition of property and equipment

(97,435)

(60,887)

Acquisition of intangibles assets

(43,290)

(12,741)

Dividends received

5,770

-

Restricted cash

8,103

3,886

Payments of notes payable

(8,015)

(3,847)

Acquisition of subsidiaries, net of cash acquired

(917,264)

(450,259)

Net cash flows used in investing activities

(1,052,131)

(523,848)

Financing activities

Payments of loans and financing

(130,446)

(106,019)

Issuance of loans and financing

809,539

100,911

Payments of lease liabilities

(61,909)

(40,527)

Treasury shares

(98,541)

-

Proceeds from exercise of stock options

32,721

-

Proceeds from issuance of common shares

-

389,170

Shares issuance cost

-

(19,704)

Dividends paid to non-controlling interests

(15,663)

(8,622)

Net cash flows from financing activities

535,701

315,209

Net foreign exchange differences

(18,376)

21,746

Net increase in cash and cash equivalents

(6,108)

122,023

Cash and cash equivalents at the beginning of the period

1,045,042

943,209

Cash and cash equivalents at the end of the period

1,038,934

1,065,232

Reconciliation between Adjusted EBITDA and Net Income

Reconciliation between Adjusted EBITDA and Net Income

(in thousands of R$)

For the three months period ended
September 30,

For the nine months period ended
September 30,

2021

2020

% Chg

2021

2020

% Chg

Net income

57,989

79,575

-27.1%

193,282

247,131

-21.8%

Net financial result

35,397

11,620

204.6%

123,681

9,642

1182.7%

Income taxes expense

5,017

4,690

7.0%

18,546

17,088

8.5%

Depreciation and amortization

45,289

26,399

71.6%

112,204

77,729

44.4%

Interest received (1)

9,857

4,142

138.0%

17,947

9,469

89.5%

Income share associate

-3,004

-1,488

101.9%

-8,626

-6,393

34.9%

Share-based compensation

8,847

10,052

-12.0%

33,949

24,649

37.7%

Non-recurring expenses:

32,008

14,279

124.2%

68,726

28,750

139.0%

- Integration of new companies (2)

5,192

2,761

88.0%

12,728

7,743

64.4%

- M&A advisory and due diligence (3)

8,442

3,709

127.6%

11,998

9,345

28.4%

- Expansion projects (4)

3,069

795

286.0%

6,459

2,886

123.8%

- Restructuring expenses (5)

6,414

3,101

106.8%

11,332

4,863

133.0%

- Mandatory Discounts in Tuition Fees (6)

8,891

3,914

127.2%

26,209

3,914

569.6%

Adjusted EBITDA

191,400

149,269

28.2%

559,709

408,065

37.2%

Adjusted EBITDA Margin

41.3%

47.6%

-630 bps

44.9%

47.5%

-260 bps

(1) Represents the interest received on late payments of monthly tuition fees.

(2) Consists of expenses related to the integration of newly acquired companies.

(3) Consists of expenses related to professional and consultant fees in connection with due diligence services for our M&A transactions.

(4) Consists of expenses related to professional and consultant fees in connection with the opening of new campuses.

(5) Consists of expenses related to the employee redundancies in connection with the organizational restructuring of our acquired companies.

(6) Consists of mandatory discounts in tuition fees granted by state decrees and individual/collective legal proceedings due COVID 19 on site classes restriction and excludes recognized revenue that relates to discounts that were granted in 2H2020, but were invoiced in 1H21, based on the Supreme Court decision that was released in December 28, 2020.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211122006685/en/

Contacts

Renata Couto, Director of Investor Relations
Phone: +55 31 3515.7564 | +55 31 98463.3341
E-mail: renata.couto@afya.com.br

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting